請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54250
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林晉玄(Ching-Hsuan Lin) | |
dc.contributor.author | Wei-Hsuan Lo | en |
dc.contributor.author | 羅唯瑄 | zh_TW |
dc.date.accessioned | 2021-06-16T02:46:44Z | - |
dc.date.available | 2022-09-30 | |
dc.date.copyright | 2020-08-06 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-03 | |
dc.identifier.citation | 1. Gow, N.A.R., A developmental program for Candida commensalism. Nature Genetics, 2013. 45(9): p. 967-968. 2. Weig, M., U. Groß, and F. Mühlschlegel, Clinical aspects and pathogenesis of Candida infection. Trends in microbiology, 1998. 6(12): p. 468-470. 3. Eggimann, P., J. Garbino, and D. Pittet, Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis, 2003. 3(11): p. 685-702. 4. Martins, N., et al., Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia, 2014. 177(5-6): p. 223-240. 5. Hesstvedt, L., et al., The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infectious Diseases, 2019. 51(6): p. 425-434. 6. Manolakaki, D., et al., Candida infection and colonization among trauma patients. Virulence, 2010. 1(5): p. 367-375. 7. Pappas, P.G., et al., Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases, 2004. 38(2): p. 161-189. 8. Achkar, J.M. and B.C. Fries, Candida infections of the genitourinary tract. Clinical microbiology reviews, 2010. 23(2): p. 253-273. 9. Kullberg, B.J. and M.C. Arendrup, Invasive candidiasis. New England Journal of Medicine, 2015. 373(15): p. 1445-1456. 10. Netea, M.G., et al., An integrated model of the recognition of Candida albicans by the innate immune system. Nature Reviews Microbiology, 2008. 6(1): p. 67-78. 11. Epstein, J.B. and B. Polsky, Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther, 1998. 20(1): p. 40-57. 12. Cauchie, M., S. Desmet, and K. Lagrou, Candida and its dual lifestyle as a commensal and a pathogen. Research in Microbiology, 2017. 168(9): p. 802-810. 13. Bauters, T.G.M., et al., Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. American Journal of Obstetrics and Gynecology, 2002. 187(3): p. 569-574. 14. Beigi, R.H., et al., Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol, 2004. 104(5 Pt 1): p. 926-30. 15. Calderone, R.A. and W.A. Fonzi, Virulence factors of Candida albicans. Trends in microbiology, 2001. 9(7): p. 327-335. 16. Sobel, J.D., et al., Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. American Journal of Obstetrics and Gynecology, 1998. 178(2): p. 203-211. 17. Fidel, P.L., Jr. and J.D. Sobel, Immunopathogenesis of recurrent vulvovaginal candidiasis. Clinical microbiology reviews, 1996. 9(3): p. 335-348. 18. Sobel, J.D., The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep, 2006. 8(6): p. 427-33. 19. Weinstein, R.A. and S.K. Fridkin, The Changing Face of Fungal Infections in Health Care Settings. Clinical Infectious Diseases, 2005. 41(10): p. 1455-1460. 20. Wisplinghoff, H., et al., Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clinical Infectious Diseases, 2004. 39(3): p. 309-317. 21. Butler, G., et al., Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature, 2009. 459(7247): p. 657-662. 22. Miller, M.G. and A.D. Johnson, White-Opaque Switching in Candida albicans Is Controlled by Mating-Type Locus Homeodomain Proteins and Allows Efficient Mating. Cell, 2002. 110(3): p. 293-302. 23. Slutsky, B., et al., quot;White-opaque transition quot;: a second high-frequency switching system in Candida albicans. Journal of Bacteriology, 1987. 169(1): p. 189. 24. Lohse, M.B. and A.D. Johnson, White–opaque switching in Candida albicans. Current Opinion in Microbiology, 2009. 12(6): p. 650-654. 25. Rai, L.S., et al., Epigenetic determinants of phenotypic plasticity in Candida albicans. Fungal Biology Reviews, 2018. 32(1): p. 10-19. 26. Si, H., et al., Candida albicans white and opaque cells undergo distinct programs of filamentous growth. PLoS pathogens, 2013. 9(3). 27. Sudbery, P.E., Growth of Candida albicans hyphae. Nature Reviews Microbiology, 2011. 9(10): p. 737-748. 28. Lorenz, M.C., J.A. Bender, and G.R. Fink, Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryotic cell, 2004. 3(5): p. 1076-1087. 29. Sudbery, P., N. Gow, and J. Berman, The distinct morphogenic states of Candida albicans. Trends in Microbiology, 2004. 12(7): p. 317-324. 30. Guinea, J., Global trends in the distribution of Candida species causing candidemia. Clinical Microbiology and Infection, 2014. 20: p. 5-10. 31. Puig-Asensio, M., et al., Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect, 2014. 20(4): p. O245-54. 32. Nucci, M., et al., Epidemiology of candidemia in Latin America: a laboratory-based survey. PloS one, 2013. 8(3): p. e59373-e59373. 33. Tan, B.H., et al., Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clinical Microbiology and Infection, 2015. 21(10): p. 946-953. 34. Chai, L.Y., D.W. Denning, and P. Warn, Candida tropicalis in human disease. Crit Rev Microbiol, 2010. 36(4): p. 282-98. 35. Barchiesi, F., et al., Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrobial agents and chemotherapy, 2000. 44(6): p. 1578-1584. 36. Prasad, R., A.H. Shah, and M.K. Rawal, Antifungals: mechanism of action and drug resistance, in Yeast Membrane Transport. 2016, Springer. p. 327-349. 37. Carrillo-Munoz, A., et al., Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter, 2006. 19(2): p. 130-9. 38. Ghannoum, M.A. and L.B. Rice, Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clinical Microbiology Reviews, 1999. 12(4): p. 501. 39. EUCAST Technical Note on fluconazole. Clinical Microbiology and Infection, 2008. 14(2): p. 193-195. 40. White, T.C., K.A. Marr, and R.A. Bowden, Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical microbiology reviews, 1998. 11(2): p. 382-402. 41. Vanden Bossche, H., P. Marichal, and F.C. Odds, Molecular mechanisms of drug resistance in fungi. Trends in Microbiology, 1994. 2(10): p. 393-400. 42. Lass-Flörl, C., et al., EUCAST technical note on amphotericin B. Clinical Microbiology and Infection, 2011. 17(12): p. E27-E29. 43. Sanglard, D. and F.C. Odds, Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet infectious diseases, 2002. 2(2): p. 73-85. 44. Forastiero, A., et al., Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrobial agents and chemotherapy, 2013. 57(10): p. 4769-4781. 45. Anderson, J.B., Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nature Reviews Microbiology, 2005. 3(7): p. 547-556. 46. Fisher, M.C., et al., Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science, 2018. 360(6390): p. 739. 47. Pfaller, M.A., Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. The American journal of medicine, 2012. 125(1): p. S3-S13. 48. Balashov, S.V., S. Park, and D.S. Perlin, Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother, 2006. 50(6): p. 2058-63. 49. Matica, M.A., et al., Chitosan as a Wound Dressing Starting Material: Antimicrobial Properties and Mode of Action. International journal of molecular sciences, 2019. 20(23): p. 5889. 50. Lopez-Moya, F., et al., Chitosan inhibits septin-mediated plant infection by the rice blast fungus Magnaporthe oryzae in a Protein Kinase C and Nox1 NADPH oxidase-dependent manner. bioRxiv, 2020: p. 2020.05.15.098657. 51. Lopez-Moya, F., M. Suarez-Fernandez, and L.V. Lopez-Llorca, Molecular mechanisms of chitosan interactions with fungi and plants. International journal of molecular sciences, 2019. 20(2): p. 332. 52. Rabea, E.I., et al., Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules, 2003. 4(6): p. 1457-1465. 53. Verlee, A., S. Mincke, and C.V. Stevens, Recent developments in antibacterial and antifungal chitosan and its derivatives. Carbohydrate polymers, 2017. 164: p. 268-283. 54. Allan, C.R., A. CR, and H. LE, The fungicidal effect of chitosan on fungi of varying cell wall composition. 1979. 55. Kumar, M.N.R., A review of chitin and chitosan applications. Reactive and functional polymers, 2000. 46(1): p. 1-27. 56. Galván Márquez, I., et al., Disruption of protein synthesis as antifungal mode of action by chitosan. International Journal of Food Microbiology, 2013. 164(1): p. 108-112. 57. Hadwiger, L., et al., Chitosan both activates genes in plants and inhibits RNA synthesis in fungi, in Chitin in nature and technology. 1986, Springer. p. 209-214. 58. Lopez-Moya, F., et al., Carbon and nitrogen limitation increase chitosan antifungal activity in Neurospora crassa and fungal human pathogens. Fungal Biology, 2015. 119(2): p. 154-169. 59. Tayel, A.A., et al., Anticandidal action of fungal chitosan against Candida albicans. International Journal of Biological Macromolecules, 2010. 47(4): p. 454-457. 60. Zakrzewska, A., et al., Transcriptional response of Saccharomyces cerevisiae to the plasma membrane-perturbing compound chitosan. Eukaryotic cell, 2005. 4(4): p. 703-715. 61. Zheng, L.-Y. and J.-F. Zhu, Study on antimicrobial activity of chitosan with different molecular weights. Carbohydrate polymers, 2003. 54(4): p. 527-530. 62. Shih, P.Y., et al., A Potential Antifungal Effect of Chitosan Against Candida albicans Is Mediated via the Inhibition of SAGA Complex Component Expression and the Subsequent Alteration of Cell Surface Integrity. Front Microbiol, 2019. 10: p. 602. 63. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect, 2008. 14(4): p. 398-405. 64. Meletiadis, J., et al., Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother, 2010. 54(2): p. 602-9. 65. Shapiro, R.S., N. Robbins, and L.E. Cowen, Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiology and molecular biology reviews : MMBR, 2011. 75(2): p. 213-267. 66. Palma-Guerrero, J., et al., Membrane fluidity determines sensitivity of filamentous fungi to chitosan. Molecular Microbiology, 2010. 75(4): p. 1021-1032. 67. Schneider, H., G.F. Fuhrmann, and A. Fiechter, Plasma membrane from Candida tropicalis grown on glucose or hexadecane. II. Biochemical properties and substrate-induced alterations. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1979. 554(2): p. 309-322. 68. Ghannoum, M., et al., Dimorphism-associated variations in the lipid composition of Candida albicans. Microbiology, 1986. 132(8): p. 2367-2375. 69. Murayama, S.Y., et al., Construction and functional analysis of fatty acid desaturase gene disruptants in Candida albicans. Microbiology, 2006. 152(5): p. 1551-1558. 70. Palmeira-de-Oliveira, A., et al., The relationship between Candida species charge density and chitosan activity evaluated by ion-exchange chromatography. Journal of Chromatography B, 2011. 879(31): p. 3749-3751. 71. Xu, J., et al., Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant Candida albicans by Competitively Inhibiting Efflux Pump. Frontiers in Cellular and Infection Microbiology, 2019. 9(211). 72. Zakrzewska, A., et al., Cellular processes and pathways that protect Saccharomyces cerevisiae cells against the plasma membrane-perturbing compound chitosan. Eukaryotic cell, 2007. 6(4): p. 600-608. 73. Palacios, D.S., et al., Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities. Proceedings of the National Academy of Sciences, 2011. 108(17): p. 6733. 74. Gray, K.C., et al., Amphotericin primarily kills yeast by simply binding ergosterol. Proceedings of the National Academy of Sciences, 2012. 109(7): p. 2234. 75. Walker, L.A., N.A. Gow, and C.A. Munro, Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrobial agents and chemotherapy, 2013. 57(1): p. 146-154. 76. Walker, L.A., N.A.R. Gow, and C.A. Munro, Fungal echinocandin resistance. Fungal Genetics and Biology, 2010. 47(2): p. 117-126. 77. Lima, S.L., A.L. Colombo, and J.N. de Almeida Junior, Fungal Cell Wall: Emerging Antifungals and Drug Resistance. Frontiers in Microbiology, 2019. 10(2573). 78. Denning, D.W., Echinocandin antifungal drugs. The Lancet, 2003. 362(9390): p. 1142-1151. 79. Munro, C.A., et al., The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Molecular microbiology, 2007. 63(5): p. 1399-1413. 80. Karababa, M., et al., CRZ1, a target of the calcineurin pathway in Candida albicans. Molecular microbiology, 2006. 59(5): p. 1429-1451. 81. Yang, F., et al., Tolerance to caspofungin in Candida albicans is associated with at least three distinctive mechanisms that govern expression of FKS genes and cell wall remodeling. Antimicrobial agents and chemotherapy, 2017. 61(5): p. e00071-17. 82. Arias, L.S., et al., Chitosan ameliorates Candida auris virulence in a Galleria mellonella infection model. Antimicrobial Agents and Chemotherapy, 2020. 83. Mesa-Arango, A.C., et al., The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast. Medical Mycology, 2013. 51(5): p. 461-472. 84. Bennett, R.J. and A.D. Johnson, The role of nutrient regulation and the Gpa2 protein in the mating pheromone response of C. albicans. Molecular Microbiology, 2006. 62(1): p. 100-119. 85. Chien, H.-F., et al., The use of chitosan to enhance photodynamic inactivation against Candida albicans and its drug-resistant clinical isolates. International journal of molecular sciences, 2013. 14(4): p. 7445-7456. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54250 | - |
dc.description.abstract | 白色念珠菌 (Candida albicans) 為人體常見的伺機性致病真菌,常存在於人體的口腔、生殖道、腸胃道及皮膚表面當中,當宿主免疫力低下或缺失時,便有可能造成入侵感染,甚至造成全身性感染進而死亡。目前在臨床上治療念珠菌感染的方式主要依靠抗真菌藥物的使用,但由於廣泛的使用抗真菌藥物,使得抗藥性菌株的出現逐漸增加,所以尋找新的治療方式有其重要性。有研究指出幾丁聚醣 (chitosan) 在pH低於6.3的情況下會帶正電,具有抗微生物的效果,且具有生物可降解性、生物相容性及低毒性等特性,有潛力開發作為新抗真菌治療方式,但目前幾丁聚醣的抗菌機制仍未明瞭。本研究致力研究白色念珠菌 (Candida albicans) 跟不同分子量的幾丁聚醣之間的相互關係,並將幾丁聚醣與抗真菌藥物結合,觀察兩者之間是否有協同殺菌作用 (synergistic antifungal effect) 。由實驗結果顯示,不同分子量的幾丁聚醣跟抗真菌藥物Fluconazole結合後,對白色念珠菌具有較好的協同抗菌效果。接著我們又測試了白色念珠菌臨床抗藥性分離株和不同物種的念珠菌熱帶念珠菌 (Candida tropicalis) 及其臨床分離抗藥性菌株,同樣發現將不同分子量的幾丁聚醣跟抗真菌藥物Fluconazole結合後,都具有較好的協同抗菌效果。本研究發現當抗真菌藥物Fluconazole跟幾丁聚醣結合後能夠以較低的劑量就達到抗菌效果,期待未來能進一步開發為新治療方式。 | zh_TW |
dc.description.abstract | Candida species are wildly found in (on) human body, but they are able to shift from commensals to pathogens if the immune system is impaired. Challenges are the limited current therapeutic options for fungal infections and the potential adverse drug reactions. Besides, the available antifungal drugs are ineffective against new and drug-resistant strains. Thus, searching and development of new drugs or alternative therapeutic methods to control this fungus have become a demanding work. Chitosan, [poly-(β-1/4)-2-amino-2-deoxy-D-glucopyranose], derived from deacetylated chitin, has great potential against microbial infection owing to its biocompatibility, biodegradability, and low toxicity. However, the antimicrobial activity of chitosan is highly associated with the deacetylation degree, pH and its molecular weight. In this study, we investigated the antifungal activity of different types and properties of chitosan against Candida species. Results showed that fluconazole, but not amphotericin B and caspofungin, in combination with any one of chitosan is able to enhance antifungal activity against Candida albicans, Candida tropicalis, and its drug-resistant isolates. FICindex (fractional inhibitory concentration) performed by checkerboard assays also determined a synergistic antifungal activity against C. albicans, C. tropicalis, and its drug-resistant isolates when treatment with chitosan-fluconazole simultaneously. These findings provide a strong evidence that chitosan in combination with fluconazole is a promising therapy against Candida species and drug-resistant strains. The data also encourages further in vivo experiments to validate our findings, in which it will provide useful guidelines for us to develop a better way and formulation to manage fungal pathogens. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:46:44Z (GMT). No. of bitstreams: 1 U0001-0308202017431900.pdf: 3501239 bytes, checksum: 3ac6951ef0aadc3fe99505a4f7406548 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 i 中文摘要 ii 英文摘要 iii 目錄 v 表目錄 viii 圖目錄 ix 前言 1 念珠菌症 (Candidiasis) 1 白色念珠菌 (Candida albicans) 2 非白色念珠菌念珠菌屬:熱帶念珠菌 (Candida tropicalis) 4 抗真菌藥物 (Antifungal drug) 6 抗藥性菌株 7 幾丁聚醣 (Chitosan) 8 研究動機 10 實驗材料與方法 11 實驗常用藥品與試劑 11 實驗常用的培養基 11 RPMI 1640培養基 11 幾丁聚醣溶液 (Chitosan stock) 11 抗真菌藥物溶液 (Antifungal drug stock) 12 最小抑制濃度分析 (Minimum Inhibitory Concentration Assay, MIC) 12 棋盤格分析(Checkerboard assay) 14 幾丁聚醣 (Chitosan) 培養基 15 紙錠擴散試驗 (Disk diffusion assay) 16 實驗結果 17 不同分子量的幾丁聚醣對於白色念珠菌野生株 (SC5314) 皆具有抑制效果 17 棋盤格分析實驗測試在白色念珠菌中幾丁聚醣和抗真菌藥物結合的關係 18 棋盤格分析發現在白色念珠菌中幾丁聚醣跟Fluconazole結合具有協同作用 19 棋盤格分析發現在白色念珠菌中幾丁聚醣跟Amphotericin B結合具有拮抗作用 19 棋盤格分析發現在白色念珠菌中幾丁聚醣跟Caspofungin結合具有拮抗作用 20 紙錠擴散實驗同樣發現幾丁聚醣跟Fluconazole結合後對白色念珠菌具有協同效果 20 紙錠擴散實驗同樣發現幾丁聚醣跟Amphotericin B結合後對白色念珠菌具有拮抗效果 21 紙錠擴散實驗同樣發現幾丁聚醣跟Caspofungin結合後對白色念珠菌具有拮抗效果 22 不同分子量的幾丁聚醣對於白色念珠菌臨床分離抗藥性菌株具有抑制效果 22 棋盤格分析發現在白色念珠菌臨床分離抗藥性菌株中幾丁聚醣跟Fluconazole結合具有協同作用 24 紙錠擴散實驗同樣發現幾丁聚醣跟Fluconazole結合後對白色念珠菌臨床分離抗藥性菌株具有協同效果 24 不同分子量的幾丁聚醣對於熱帶念珠菌標準株 (YL477) 具有抑制效果 25 棋盤格分析發現在熱帶念珠菌標準株中幾丁聚醣跟Fluconazole結合具有協同作用 26 紙錠擴散實驗同樣發現幾丁聚醣跟Fluconazole結合後對熱帶念珠菌具有協同效果 27 不同分子量的幾丁聚醣對於熱帶念珠菌臨床分離抗藥性菌株 (YL1807) 具有抑制效果 27 棋盤格分析發現在熱帶念珠菌臨床分離抗藥性菌株中幾丁聚醣跟Fluconazole結合具有協同作用 28 紙錠擴散實驗同樣發現幾丁聚醣跟Fluconazole結合後對熱帶念珠菌臨床分離抗藥性菌株具有協同效果 29 討論 30 結論 35 未來研究方向 36 圖表 37 參考文獻 56 附錄 65 | |
dc.language.iso | zh-TW | |
dc.title | 合併使用幾丁聚醣和抗真菌藥物Fluconazole對白色念珠菌和熱帶念珠菌及臨床分離抗藥性菌株具有協同殺菌效果 | zh_TW |
dc.title | Synergistic antifungal activity of chitosan with fluconazole against Candida albicans and Candida tropicalis and its clinical isolates | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 羅秀容(Hsiu-Jung Lo),呂俊毅(Jun-Yi Leu),陳進庭(Chin-Tin Chen),薛雁冰(Yen-Ping Hsueh),孫培倫(Pei-Lun Sun) | |
dc.subject.keyword | 白色念珠菌,幾丁聚醣,抗真菌藥物,協同抗菌作用,熱帶念珠菌,臨床分離抗藥性菌株, | zh_TW |
dc.subject.keyword | Candida albicans,chitosan,antifungal drug,synergistic antifungal effect,Candida tropicalis,clinical isolates, | en |
dc.relation.page | 80 | |
dc.identifier.doi | 10.6342/NTU202002301 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-04 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0308202017431900.pdf 目前未授權公開取用 | 3.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。